No connection

Search Results

NEO

NEUTRAL
$8.35 Live
NeoGenomics, Inc. · NASDAQ
Target $14.81 (+77.4%)
$4.72 52W Range $13.74
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 15, 2026
Market cap
$1.09B
P/E
N/A
ROE
-12.4%
Profit margin
-14.9%
Debt/Equity
0.49
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
80%
NeoGenomics exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and exceptional liquidity (Current Ratio 4.26), though it remains unprofitable with a -14.85% profit margin. While the company has a remarkable track record of beating earnings estimates and shows positive YoY EPS growth, this is offset by a disastrous 5-year price decline of 83.1% and bearish insider activity. The stock appears undervalued relative to analyst targets ($14.81), but the lack of current profitability and negative technical trends suggest a speculative recovery play rather than a value certainty.

Key Strengths

Exceptional short-term liquidity with a Current Ratio of 4.26
Consistent history of earnings beats (3/4 last 4 quarters)
Low leverage with a Debt/Equity ratio of 0.49
Positive revenue growth (10.60% YoY) and EPS growth (20% YoY)
Significant upside potential relative to analyst target price of $14.81

Key Risks

Persistent negative profit margins (-14.85%) and operating margins
Strong bearish technical trend with a 5-year decline of 83.1%
Bearish insider sentiment with sales from the President and General Counsel
Negative Return on Equity (-12.43%) indicating inefficient capital use
High dependence on future profitability to justify forward P/E of 26.17
AI Fair Value Estimate
Based on comprehensive analysis
$11.5
+37.7% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
41
Moderate
Value
60
Future
55
Past
20
Health
70
Dividend
0
AI Verdict
Speculative Recovery
Key drivers: Strong balance sheet liquidity, Consistent earnings surprises, Chronic lack of profitability, Severe long-term price depreciation
Confidence
85%
Value
60/100

Trades at a discount to book value and sales, but lacks a Graham Number due to negative earnings.

Positives
  • Low Price/Book (1.29)
  • Low Price/Sales (1.49)
Watchpoints
  • No current P/E due to losses
  • Forward P/E of 26.17 is moderate but requires earnings realization
Future
55/100

Growth is present but modest; the primary driver is the narrowing of losses.

Positives
  • 10.6% Revenue growth
  • Strong EPS surprise trend
Watchpoints
  • Slow revenue growth relative to high-growth healthcare peers
Past
20/100

Long-term historical performance is extremely poor.

Positives
  • Recent 1-week and 1-month positive momentum
Watchpoints
  • 5Y Change: -83.1%
  • 3Y Change: -45.5%
Health
70/100

Balance sheet is robust, but operational efficiency is lacking.

Positives
  • Piotroski F-Score 5/9 (Stable)
  • Very high Quick Ratio (3.61)
  • Low Debt/Equity (0.49)
Watchpoints
  • Negative ROA and ROE
Dividend
0/100

Company is in a growth/recovery phase and does not distribute capital.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$8.35
Analyst Target
$14.81
Upside/Downside
+77.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for NEO and closest competitors.

Updated 2026-04-14
NEO
NeoGenomics, Inc.
Primary
5Y
-83.1%
3Y
-45.5%
1Y
-14.1%
6M
-11.0%
1M
+1.3%
1W
+3.6%
IVA
Inventiva S.A.
Peer
5Y
-63.3%
3Y
+67.0%
1Y
+70.8%
6M
+15.6%
1M
-20.7%
1W
-3.8%
INN
InnovAge Holding Corp.
Peer
5Y
-65.5%
3Y
+9.5%
1Y
+197.1%
6M
+60.5%
1M
-4.5%
1W
+7.8%
ABC
AbCellera Biologics Inc.
Peer
5Y
-90.7%
3Y
-53.9%
1Y
+45.4%
6M
-21.9%
1M
+11.5%
1W
+1.2%
PNT
The Pennant Group, Inc.
Peer
5Y
-26.0%
3Y
+129.2%
1Y
+16.1%
6M
+27.2%
1M
-7.9%
1W
-4.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
26.17
PEG Ratio
N/A
P/B Ratio
1.29
P/S Ratio
1.49
EV/Revenue
1.83
EV/EBITDA
-732.44
Market Cap
$1.09B

Profitability

Profit margins and return metrics

Profit Margin -14.85%
Operating Margin -6.56%
Gross Margin 43.16%
ROE -12.43%
ROA -2.9%

Growth

Revenue and earnings growth rates

Revenue Growth +10.6%
Earnings Growth N/A
Q/Q Revenue Growth +10.56%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.49
Low debt
Current Ratio
4.26
Strong
Quick Ratio
3.61
Excellent
Cash/Share
$1.23

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.2B
Gross Margin
43.8%
Op. Margin
-6.7%
Net Margin
-5.2%
Total Assets
$1.4B
Liabilities
$0.5B
Equity
$0.8B
Debt/Equity
0.63x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
-486%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-28
$N/A
2026-02-17
$0.06
+50.0% surprise
2025-10-28
$0.03
+25.8% surprise
2025-07-29
$0.03
+21.9% surprise

Healthcare Sector Comparison

Comparing NEO against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-12.43%
This Stock
vs
-101.52%
Sector Avg
-87.8% (Below Avg)
Profit Margin
-14.85%
This Stock
vs
-12.47%
Sector Avg
+19.1% (Superior)
Debt to Equity
0.49
This Stock
vs
3.4
Sector Avg
-85.6% (Less Debt)
Revenue Growth
10.6%
This Stock
vs
124.21%
Sector Avg
-91.5% (Slower)
Current Ratio
4.26
This Stock
vs
4.56
Sector Avg
-6.6% (Weaker)

Similar Companies

Peer comparison within the same industry

NEO NeoGenomics, Inc.
NEUTRAL
Mkt Cap
$1.1B
P/E
-
ROE
-12.4%
Price
$8.35
IVA Inventiva S.A.
NEUTRAL
Mkt Cap
$1.1B
P/E
-
ROE
-%
Price
$5.26
 Compare with NEO
INNV InnovAge Holding Corp.
BEARISH
Mkt Cap
$1.1B
P/E
164.0
ROE
1.2%
Price
$8.2
 Compare with NEO
ABCL AbCellera...
NEUTRAL
Mkt Cap
$1.1B
P/E
-
ROE
-14.5%
Price
$3.49
 Compare with NEO
PNTG The Pennant Group, Inc.
BULLISH
Mkt Cap
$1.1B
P/E
36.2
ROE
9.8%
Price
$30.42
 Compare with NEO

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

ZOOK ANTHONY P
Chief Executive Officer
Stock Award
2026-04-01
140,498 shares
STONE WARREN
President
Stock Award
2026-04-01
17,562 shares
SHERMAN JEFFREY SCOTT
Chief Financial Officer
Stock Award
2026-02-23
57,693 shares
OLIVO ALICIA C
General Counsel
Stock Award
2026-02-23
29,522 shares
STONE WARREN
President
Stock Award
2026-02-23
36,548 shares
AUNAN GREGORY D
Officer
Stock Award
2026-02-20
6,323 shares
STONE WARREN
President
Sell
2026-01-20
22,128 shares · $276,682
OLIVO ALICIA C
General Counsel
Stock Award
2026-01-13
59,382 shares
STONE WARREN
President
Stock Award
2026-01-13
59,382 shares
OLIVO ALICIA C
General Counsel
Sell
2025-11-25
20,916 shares · $250,992
OLIVO ALICIA C
General Counsel
Option Exercise
2025-11-25
8,977 shares · $90,219
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
8 analysts
Piper Sandler
2026-02-24
Maintains
Overweight Overweight
Needham
2026-02-17
Maintains
Buy Buy
Needham
2026-01-12
reit
Buy Buy

Past News Coverage

Recent headlines mentioning NEO from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile